Erythrocytosis and Variants of EPO | NEJM
The author describes the scientific foundations and implications of a study on variant EPO and erythrocytosis.
Related Articles
Anticoagulation or Antiplatelet Therapy for Device-Detected Atrial Fibrillation | NEJM
This feature about a woman with device-detected atrial fibrillation offers a case vignette accompanied by two essays, one supporting the initiation of anticoagulant therapy and…
Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis | NEJM
Semaglutide, a glucagon-like peptide-1 receptor agonist, is a candidate for the treatment of metabolic dysfunction–associated steatohepatitis (MASH). In this ongoing phase 3, multicenter, randomize…
Southern Tick-Associated Rash Illness | NEJM
A 65-year-old man presented with 1-day history of a rash with a bull’s-eye appearance on his left hip. One week earlier, he had removed a…
Lepodisiran — A Long-Duration Small Interfering RNA Targeting Lipoprotein(a) | NEJM
Elevated lipoprotein(a) concentrations are associated with atherosclerotic cardiovascular disease. The safety and efficacy of lepodisiran, an extended-duration, small interfering RNA targeting hepa…
Lentiviral Gene Therapy for Severe Leukocyte Adhesion Deficiency Type 1 | NEJM
The β2 common integrin subunit CD18 is essential for leukocyte–endothelial adhesion and extravasation to inflamed or infected tissue. Damaging variants in ITGB2, which encodes CD18,…
Lepodisiran — A Long-Duration Small Interfering RNA Targeting Lipoprotein(a) | NEJM
Elevated lipoprotein(a) concentrations are associated with atherosclerotic cardiovascular disease. The safety and efficacy of lepodisiran, an extended-duration, small interfering RNA targeting hepa…
Lepodisiran — A Long-Duration Small Interfering RNA Targeting Lipoprotein(a) | NEJM
Elevated lipoprotein(a) concentrations are associated with atherosclerotic cardiovascular disease. The safety and efficacy of lepodisiran, an extended-duration, small interfering RNA targeting hepa…
Identification of Hepatic-like EPO as a Cause of Polycythemia | NEJM
Secondary erythrocytosis often results from conditions that cause tissue hypoxia or an improper increase in erythropoietin (EPO) production. EPO, the major regulator of erythropoiesis, has…
Anticoagulation or Antiplatelet Therapy for Device-Detected Atrial Fibrillation | NEJM
This feature about a woman with device-detected atrial fibrillation offers a case vignette accompanied by two essays, one supporting the initiation of anticoagulant therapy and…
Anticoagulation or Antiplatelet Therapy for Device-Detected Atrial Fibrillation | NEJM
This feature about a woman with device-detected atrial fibrillation offers a case vignette accompanied by two essays, one supporting the initiation of anticoagulant therapy and…